Vivos - RDGL STOCK NEWS

On January 11, 2023, Vivos Inc. (OTCQB: RDGL) announced the filing of a utility patent application for a range of particles used in precision radionuclide therapy, following a provisional patent from January 15, 2022. The application covers several countries, including Canada, the EU, Japan, and China. Dr. Mike Korenko emphasized the importance of precision radionuclide therapy in future cancer treatments, particularly through their IsoPet and RadioGel therapies, which deliver localized radiation to tumors, minimizing side effects compared to traditional therapies.

Vivos Inc. (OTCQB: RDGL) has filed a provisional patent application for a new system supporting precision radionuclide therapy. This includes shipping containers, a shielded vial holder, a Peltier chiller, and syringe shields, designed to enhance treatment efficacy and safety for tumors ranging from small human lymph nodes to larger equine tumors. The equipment aims to address concerns from clinical trials regarding contamination and radiation safety, receiving positive feedback from therapists. The company plans to provide this technology for human clinical trials at Mayo Clinic.

Vivos Inc. (OTCQB: RDGL) announced on September 14, 2022, the filing of a patent application for its hydrogel component of IsoPet and RadioGel in the USA and internationally. This development follows the recent Notice of Allowance for a patent related to their yttrium phosphate microparticles. The optimized hydrogel aims to enhance gelation and resorption characteristics while meeting FDA standards. Vivos continues to focus on strong intellectual property protection as part of its strategy to advance injectable radionuclide therapies for treating tumors in both animals and humans.

Vivos Inc. (OTCQB: RDGL) has certified the New England Equine Practice in Patterson, NY, to administer Precision Radionuclide IsoPet^® therapy for solid tumors in horses. This innovative therapy allows for same-day treatment using low activity to deliver high doses localized at the injection site, minimizing contamination. The company is exploring expansion to mobile treatment options to prevent horse travel-related health issues. Additionally, a successful demonstration at the University of Missouri has shown effective long-term results, with the treated horse remaining cancer-free after fifteen months.

Vivos Inc. (OTCQB: RDGL) has expanded its intellectual property protection by filing a particle patent in over ten patent offices, covering 63 countries. A provisional patent (63-299,930) was also filed, enhancing protection for hydrogel and particle components. The company plans to file additional claims internationally via the PCT process and a new utility patent for hydrogel innovations by Q3. Dr. Korenko emphasized the aim to strengthen their intellectual property to enhance shareholder value and establish a leadership position in precision radionuclide therapy.

Vivos Inc. (OTCQB: RDGL) has streamlined the IsoPet® therapy process by consolidating treatments into a single production run, effectively lowering production and shipping costs. This initiative was demonstrated at Johns Hopkins University, where two cats were treated using this new approach. Dr. Korenko emphasized the company's commitment to reducing costs while maintaining treatment quality for pets. Vivos' IsoPet® and RadioGel™ technologies use localized radiation for treating tumors in animals and humans, respectively, highlighting their innovation in the veterinary oncology space.

Vivos Inc. (OTCQB: RDGL) has successfully filed a particle patent in multiple countries, including the USA, EU, Japan, and others, enhancing its intellectual property strategy. The company is set to file a new utility patent for its hydrogel component later this year. This move underpins Vivos's plans to establish exclusive licensing agreements globally. Vivos has developed innovative brachytherapy treatments using Yttrium-90 for tumors in animals and humans, with its products aiming to offer effective radiation therapy while minimizing side effects.

Vivos Inc. (OTCQB: RDGL) provided a recap of its 2021 progress and future objectives. The company highlighted advancements in its IsoPet® animal therapy, including successful treatments and the formation of new regional clinics. For human therapy, RadioGel™ is undergoing FDA processes, with an upgraded Quality Management System in place. Challenges from the COVID-19 pandemic have been addressed, significantly improving hydrogel production efficiency. Financially, the company reports a strong capital structure with no toxic debt.

Vivos Inc. (OTCQB: RDGL) recently met with the FDA to discuss the Investigational Device Exemption for its RadioGel™ treatment for recurrent thyroid cancer. The FDA provided beneficial guidance, suggesting a Q-Submission path for expedited review and offering insights on clinical testing protocols. Vivos's representatives from Mayo Clinic effectively communicated the medical necessity for RadioGel™. CEO Mike Korenko noted that this pivotal meeting could prevent a rejected IDE submittal, emphasizing the company's readiness to cover costs for final IDE submission.